Roundtable Roundup: Choosing a Bispecific Antibody for R/R Multiple Myeloma
In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a patient with multiple myeloma and progressive disease.
CASE SUMMARY
- A 72-year-old man was diagnosed 6 years ago with multiple myeloma, with 60% plasma cells and translocation 14;20.
- Medical history: respiratory infections (2 episodes of pneumonia and multiple episodes of bronchitis over prior 10 years)
- He received 5 prior lines of therapy, most recently chimeric antigen receptor T-cell infusion
- He now presents with progressive disease (elevated free light chain, creatinine level of 2.3 mg/dL)
- ECOG performance status: 2
CASE UPDATE
Talquetamab is initiated via step-up dosing (SUD) up to 800 μg/kg every 2 weeks (Q2W).
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
